What is the role of neratinib in the treatment of HER2/neu-positive breast cancer?

Updated: Apr 23, 2020
  • Author: Joseph A Sparano, MD; Chief Editor: John V Kiluk, MD, FACS  more...
  • Print


Neratinib is indicated for the extended adjuvant treatment of early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy, as follows:

  • 240 mg (ie, six 40-mg tablets) PO once daily with food continuously for 1 year
  • Antidiarrheal prophylaxis required when starting therapy

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!